Suppr超能文献

疾病修饰疗法对脊髓性肌萎缩症患者肺功能和呼吸肌力量的影响:系统评价与荟萃分析

The Effect of Disease-Modifying Therapies on Lung Function and Respiratory Muscle Strength in Spinal Muscular Atrophy: Systematic Review and Meta-Analysis.

作者信息

Kant-Smits Kim, Bartels Bart, van der Heiden Laura, Veldhoen Esther S, van der Ent Kors, van der Pol W Ludo, Hulzebos Erik H J

机构信息

Ms. Kant-Smits and Drs. Bartels and Hulzebos are affiliated with Child Development and Exercise Center, Wilhelmina Children's Hospital, University Medical Center Utrecht, the Netherlands.

Ms. van der Heiden is affiliated with Fysiocompany Kortbeek, Vught, the Netherlands.

出版信息

Respir Care. 2025 Mar;70(3):337-348. doi: 10.4187/respcare.12378. Epub 2025 Jan 29.

Abstract

Spinal muscular atrophy (SMA) is often complicated by respiratory problems. The disease-modifying therapies (DMTs) (nusinersen, onasemnogene abeparvovec, and risdiplam) have improved survival, motor function, and functional muscle strength in patients with SMA, but their effects on lung function and respiratory muscle strength need further clarification. Therefore, we performed a systematic review of studies that documented the effects of DMTs on lung function and respiratory muscle strength in patients with SMA types I, II, III, and IV. We searched the electronic databases PubMed/MEDLINE, CINAHL, Embase, and Web of Science up to December 2023. We included pre-post studies that determined the effect of DMTs for SMA on lung function or respiratory muscle strength in patients with SMA. Where possible, we performed a meta-analysis using a random-effects model with generic inverse variance weighing. We included 19 studies of 376 identified records (16 longitudinal cohort studies and 3 case series) with 384 participants. Seventeen studies investigated the effect of nusinersen, and two studies investigated the effect of risdiplam. Seventeen studies had a moderate and two had a high risk of bias. Most of these studies did not report statistically significant improvement in lung function or respiratory muscle strength after treatment with nusinersen or risdiplam. A meta-analysis of 13 studies showed no statistically significant improvement in FVC after 2, 6, 10, and > 12 months of treatment with nusinersen. The findings of this review indicate that there is moderate evidence that nusinersen does not improve FVC, FEV, peak expiratory flow, or maximum inspiratory pressure in subjects with SMA types I, II, III, or IV. There was no statistically significant decline in lung function and respiratory muscle strength after treatment. This may suggest that nusinersen may have stabilized lung function and respiratory muscle strength.

摘要

脊髓性肌萎缩症(SMA)常伴有呼吸问题。疾病修正疗法(DMTs)(诺西那生钠、onasemnogene abeparvovec和利司扑兰)已改善了SMA患者的生存率、运动功能和功能性肌肉力量,但其对肺功能和呼吸肌力量的影响仍需进一步明确。因此,我们对记录DMTs对I、II、III和IV型SMA患者肺功能和呼吸肌力量影响的研究进行了系统综述。我们检索了截至2023年12月的电子数据库PubMed/MEDLINE、CINAHL、Embase和科学网。我们纳入了确定DMTs对SMA患者肺功能或呼吸肌力量影响的前后对照研究。在可能的情况下,我们使用随机效应模型和通用逆方差加权法进行了荟萃分析。我们纳入了19项研究,这些研究来自376条已识别记录(16项纵向队列研究和3个病例系列),共有384名参与者。17项研究调查了诺西那生钠的效果,两项研究调查了利司扑兰的效果。17项研究存在中度偏倚风险,两项研究存在高度偏倚风险。这些研究中的大多数未报告诺西那生钠或利司扑兰治疗后肺功能或呼吸肌力量有统计学意义的改善。对13项研究的荟萃分析显示,诺西那生钠治疗2、6、10和>12个月后,用力肺活量(FVC)无统计学意义的改善。本综述的结果表明,有中等证据表明,诺西那生钠不能改善I、II、III或IV型SMA患者的FVC、第一秒用力呼气容积(FEV)、呼气峰值流速或最大吸气压力。治疗后肺功能和呼吸肌力量没有统计学意义的下降。这可能表明诺西那生钠可能稳定了肺功能和呼吸肌力量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验